Declines in serum phosphorus over time may improve survival.
Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism.
Calcium-based and non-calcium-based binder use were associated with similar death risks.
Levels declined significantly from 7.2 to 5.0 mg/dL, data show.
Vascular calcification contributes to increased cardiovascular risk in dialysis patients.
New findings are consistent with those from previous animal studies.
PA21 comparable in safety and efficacy to sevelamer carbonate out to 52 weeks, study finds.
Serum levels vary throughout the day, and higher phosphorus intake exaggerates the early afternoon rise in serum phosphorus.
New findings raise questions "on the generalizability of previous research studies to the clinic setting," researchers conclude.
Low phosphorus increases all-cause and cardiovascular mortality only among the elderly.
Phosphorus levels are lower in postmenopausal women on estrogen replacement therapy.
Patients who take phosphate binders may be at a 22% higher risk of death that those who take other non-calcium based treatments.
Use of the agents is associated with a 29% and 22% decreased risk of all-cause and cardiovascular mortality.
A high proportion of top-selling grocery items contain phosphorus additives, and consumption may be encouraged by their lower cost.
It significantly decreased cardiovascular and all-cause mortality compared with calcium carbonate.
The increasing popularity of processed convenience foods could be a factor.
Consuming too much phosphorus increases the risk of left ventricular hypertrophy in women, study finds
Combined with use of a binder, this approach raised serum albumin while maintaining target phosphorus levels.
Factors unrelated to mineral metabolism may contribute to the association between high FGF-23 and death in dialysis patients.
Researchers made the discovery in a study of individuals with normal kidney function.
Proteinuria also is linked to high cholesterol.
Reducing phosphate burden may decrease proteinuria and slow progression of renal disease in patients with chronic kidney disease.
Nearly 11% of hemodialysis (HD) patients who discontinued use of a phosphate binder did so because of side effects.
Oral sodium bicarbonate may ease hyperphosphatemia in peritoneal dialysis (PD) patients with metabolic acidosis.
Dietary phosphorus may have an effect on the progression of autosomal dominant polycystic kidney disease.
Serum phosphorus concentrations are significantly lower in elderly hemodialysis (HD) patients compared with younger patients.
Phosphate level is a stronger predictor for increased mortality among hemodialysis (HD) patients than calcium and parathyroid hormone (PTH) levels.
Lanthanum carbonate acts in synergy with dietary phosphate restriction to decrease levels of fibroblast growth factor 23 (FGF-23) in patients with chronic kidney disease (CKD) and normal phosphate levels.
Hyperparathyroidism develops prior to significant hyperphosphatemia in patients with chronic kidney disease (CKD) but not on dialysis.
New findings presented at Kidney Week 2012 suggest that target serum phosphorus levels in patients on maintenance hemodialysis (MHD) may need to be defined.